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Limited data exist on HIV-1 drug resistance patterns in South Africa following second-line protease-inhibitor containing regimen
failure. This study examined drug resistance patterns emerging in 75 HIV-1 infected adults experiencing virologic failure on a
second-line regimen containing 2 NRTI and lopinavir/ritonavir. Ninety six percent of patients (n = 72) were infected with HIV-1
subtype C, two patients were infected with HIV-1 subtype D and one with HIV-1 subtype A1. Thirty nine percent (n = 29) of
patients had no resistance mutations in protease or reverse transcriptase suggesting that medication non-adherence was a major
factor contributing to failure. Major lopinavir resistance mutations were infrequent (5 of 75; 7%), indicating that drug resistance
is not the main barrier to future viral suppression.
1.Introduction
TheSouthAfricanantiretroviralrolloutprogrammeconsists
of a non-nucleoside reverse transcriptase inhibitor (NNRTI)
based ﬁrst-line regimen and a ritonavir-boosted protease
inhibitor (PI) containing second-line regimen. Standard
genotype analyses of ﬁrst-line failure samples from South
Africa have shown that the majority of patients remain
susceptible to the second-line regimen of zidovudine (AZT),
didanosine (ddI), and lopinavir/ritonavir (LPV/r) [1–3].
With over one million patients on antitretroviral therapy
(ART) in the South African programme, a rise in second-line
regimen failures is expected. Currently, little is known about
treatment options after second-line failure or the frequency
of protease inhibitor resistance in HIV-1 subtype C.
Patients with HIV-1 subtype B who experience virologic
failure on an initial regimen containing LPV/r infrequently
have major protease (PR) mutations detected [4]. Resistance
to LPV generally requires the accumulation of several
mutationsinthePRgenealthoughrare,singlemutationscan
reduce susceptibility [5, 6]. Several studies have identiﬁed
naturally occurring polymorphisms in subtype C PR that
may facilitate the development of PI resistance, but their
clinical signiﬁcance is uncertain [7, 8]. The current study
assessed the occurrence of known HIV-1 drug-resistance
mutations in PR and RT in patients with second-line ART
failure and the remaining treatment options.
2. Methods
2.1. Patient Samples. Plasma samples from 75 patients
on a failing second-line regimen (LPV/r and 2 NRTI)
were sent for HIV-1 drug-resistance testing from clinics
at two large state hospitals in Johannesburg, South Africa.2 AIDS Research and Treatment
Virologic failure was deﬁned as having conﬁrmed (two
consecutive measurements) of plasma HIV-1 RNA greater
than 5000copies/mL. Because pretherapy samples were not
available from these patients, PR sequences were compared
with those from 226LPV/r na¨ ıve patients on failing ﬁrst-line
ART from the same two clinics [1]. The work conducted on
these samples was with the understanding and the consent of
the human subjects.
2.2. Population Genotype Analysis. Population-based geno-
typing was performed using an in-house drug-resistance
assay. Brieﬂy, a 1.7kb amplicon was generated by RT-
initiated polymerase chain reaction encompassing the entire
PR and partial RT-coding regions. The amplicon was
sequenced using ﬁve primers that ensure bidirectional
coverage from codons 1–99 of PR and codons 1–230 of
RT. Sequencing was performed with either an ABI Prisms
3730 or an ABI Prism 3100-Avant Genetic Analyzer (Applied
Biosystems, USA).
2.3. Data and Statistical Analyses. Sequences were
assembled, manually edited using Sequencher v4.5
software (Gene codes, Ann Arbor, MI), and submitted
to the ViroScore database, which uses the IAS-USA
mutation list to identify HIV-1 drug resistance mutations
(http://www.iasusa.org/). The frequency distribution of
PR mutations was also compared in LPV/r-na¨ ıve and
-exposed patients. The REGA HIV-1 subtyping tool was
used to determine HIV-1 subtype of each patient sample
(http://www.bioafrica.net/subtypetool/html). The chi-
squared test was used to determine if the frequency of
naturally occurring polymorphisms in LPV/r-naive and -
exposed patients diﬀered signiﬁcantly. A P-value of <.01 was
considered signiﬁcant to adjust for the multiple comparisons
across PR.
3. Results
A total of 75 plasma samples were available from patients
experiencing virologic failure on a second-line LPV/r-based
regimen (Table 1). The mean age was 34 years (IQR 29–40),
69% were female (n = 52), and the average time on second-
line therapy was 16 months (range 4–54 months; Table 1).
At the time of failure, median CD4+ T-cell count and mean
HIV-1 RNA were 141cells/mm3and 184,779 copies/mL,
respectively. There was no diﬀerence in HIV-1 RNA or CD4
levels observed in patients with and without PI mutations
(P = .36 and P = .57, resp.).
Ninety six percent of patients (n = 72) were infected
withHIV-1subtypeC,twopatientswereinfectedwithHIV-1
subtype D, and one with HIV-1 subtype A1.
Twenty nine of the 75 patients (39%) had no major
mutations present in PR or the RT region examined that
would confer resistance to PI, NRTI, or NNRTI, suggesting
medication nonadherence to the second-line regimen. A
further 19 (25%) had NNRTI resistance mutations without
PI or NRTI mutations. Only ﬁve of 75 patients (7%) had
major LPV resistance mutations (Table 1). The major LPV
resistance mutations detected were M46I, L76V, and V82A,
occurring alone or in combinations of up to 5 mutations.
Sixty seven (89%) patients had one or two minor
lopinavir (LPV) resistance mutations (Figure 1). These
minor mutations would not be expected to impact the
eﬃcacy of boosted PIs [9]. Nevertheless, we compared
all 75 sequences from LPV/r-exposed patients with those
from 226LPV-na¨ ıve patients to assess if any of the minor
mutationsdetectedatfailurewerelikelytohavebeenselected
by LPV/r. There were no statistically signiﬁcant diﬀerences
between LPV-na¨ ıve and -exposed patients in the frequency
of changes in PR.
Forty-one (55%) patients had mutations in the RT
region only. Nineteen had mutations conferring resistance
to NNRTI alone, and 22 had resistance to both NRTI and
NNRTI. The most common NNRTI mutations observed
were K103N (n = 16; 21%) and V106M (n = 9; 12%;
Figure 2). Thirteen of the 75 patients (17%) had NNRTI
resistance mutations associated with reduced susceptibility
to etravirine, but only 2 of the 13 had a weighting score
of greater than 2.5 predictive of a poor virologic response
to etravirine. Of the 30 patients with NRTI resistance
mutations, 15 had the M184V mutation, 10 had TAMs
(Table 1), 1 had Q151M complex, and none had K65R. Eight
percent (n = 6) of all patients had two or more TAMs or
other resistance mutations that would cause broad NRTI
cross-resistance (Q151M).
4. Discussion
Almost half (29 of 75 [39%]) of the patients in this study on
failingsecond-linetherapy(LPV/rand2NRTIs)didnothave
detectable resistance to NRTI, NNRTI, or PI. This suggests
that medication nonadherence contributed to some of the
virologic failure observed. In support of this, a recent study
by Pulido et al. [10] showed that loss of viral suppression
on a LPV/r regimen was linked to a low baseline CD4
count or hemoglobin levels and medication nonadherence.
Nonadherence may be linked to side eﬀects arising from the
combination of ddI, AZT, or LPV/r [11], which was the most
common second-line regimen prescribed (n = 53; 71%).
Indeed, frequent toxicity was observed in a Ugandan study
of second-line therapy containing LPV/r [12].
In patients who did have evidence of drug resistance (46
of 75 [61%]), major LPV/r mutations were infrequent (5
of 46 [11%]). Overall, only 7% (5 of 75) of the patients in
this study had major LPV/r resistance mutations. The lack of
accumulationofmajormutationsinPRissimilartothatseen
in other subtype C-infected patients [13]. Thus, diﬀerences
in subtypes may inﬂuence the emergence of LPV resistance.
In addition, our results are very similar to a recent report
of 6% PI resistance in patients with viremia on second-line
therapy from Soweto, South Africa [14].
Minor LPV mutations were found in 89% (67 of
75) of patients in this study, but comparison with 226
sequences from LPV/r-na¨ ıve patients revealed that all are
likely to be naturally occurring subtype C polymorphisms.
Several PR polymorphisms in subtype C that could aﬀectAIDS Research and Treatment 3
Table 1: Patient characteristics and mutations at failure of second-line therapy.
Variable Median (inter quartile range)
Median (inter quartile range) No PI major mutations (n = 70) PI major mutations (n = 5)
Age (years) 34 (29–40)
CD4+ T-cells/mm3 141 (75–245) 138 (80–229) 246 (194–254)
HIV-1 RNA (copies/mL) 184,779 (8790–166,300) 61000 (15000–155000) 3260 (2200–33000)
Time on second-line (months) 16 (7–18)
Regimens n
LPV/r, AZT, ddI 53
LPV/r, 3TC, AZT 8
LPV/r, 3TC, TNF 4
LPV/r, 3TC, ABC 2
LPV/r, AZT, d4T 2
LPV/r, ddI, TNF 2
LPV/r, 3TC, ddI 1
LPV/r, 3TC, EFV 1
LPV/r, AZT, EFV 1
LPV/r, FTC, TNF 1
Resistance Mutations n (%)
NRTI mutations 26 (35%)
M184V 15 (20%)
K65R 0 (0%)
Q151M 1 (1%)
TAMs 10 (13%)
NNRTI mutations 39 (52%)
K103N 16 (21%)
V106M 9 (12%)
Any PR mutations (major and minor) 67 (89%)
MajorLPV mutations 5( 7 % )
M46I, L76V 1
M46I 1
L33F, I54S, V82A, I84V 1
L33F, M46I, I54V, I84V, L90M 1
M46I, I54V, L76V 1
PI susceptibility have been noted by others [8]. A recent
study by Champenois and colleagues showed that there
was no association between these polymorphisms and the
slope of viral RNA decline or time to undetectable virus
in patients receiving initial PI-based therapy, indicating
that these polymorphisms probably have little impact on
treatment response. Mutations outside of PR, at gag cleavage
sites, can reduce susceptibility to PIs but infrequently occur
without PR mutations [15].
Twenty seven percent of patients (20 of 75) had both
NRTI and NNRTI mutations. The high percentage of K103N
and V106M is likely the result of ﬁrst-line failure of a
NNRTI-containing regimen. M184V and TAMs were likely
selected by NRTI in either the ﬁrst- or second-line regimens.
However, only 15% of patients had multiple TAMs or other
multi-NRTI resistance mutations (Q151M) indicating that
NRTI could be used again in the majority of patients.
The mutation proﬁles observed indicates that several
third-line options are available after second-line failure.
The large majority of patients (93%) would have virus
that is likely to be susceptible to other boosted PI. The 4
patients with M46I would be expected to have a decreased
susceptibility to indinavir, nelﬁnavir, fosamprenavir, and
atazanavir, and the 2 patients with L76V would likely
have a reduced susceptibility to indinavir, fosamprenavir,
and darunavir. The sole patient with V82A would have
reduced susceptibility to indinavir. The virus with I54S
would be interesting to study further as the exact eﬀect of
this mutation on PI resistance is not well understood. In
addition, the second-generation NNTRI etravirine could be
eﬀective in the majority of the patients (73 of 75 [97%]),
although NNRTI mutations, including etravirine resistance
mutations, may have declined to undetectable levels without
NNRTI exposure in the second-line regimen. Additional4 AIDS Research and Treatment
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Figure 1: Comparison of changes from HXB2 reference between 45 lopinavir/r-exposed (light gray bars) versus 226LPV-na¨ ıve patients
(dark gray bars). Only L63P was signiﬁcantly more frequent in lopinavir/r-exposed than -na¨ ıve patients (P = .0435).
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Figure 2: Frequency of mutations occurring in the RT region of patients failing second-line therapy. Light gray bars indicate thymidine
analog mutations (TAMs), dark gray bars other NRTIs mutations, and black bars NNRTIs mutations.
studies would be necessary to exclude the existence of minor
populations of etravirine-resistant variants.
5. Conclusion
Major LPV resistance mutations were infrequent among
patients on a failing second-line regimen containing LPV/r
and 2 NRTI in the South African roll-out programme.
Most ritonavir-boosted PIs would be a good option for
subsequent therapy, possibly in combination with etravirine
and NRTIs. Alternatively, the integrase inhibitor raltegravir
could be used in combination with a boosted PI although
comparative data are needed. The absence of HIV-1 drug
resistance in approximately half of the patients suggests that
better tolerated regimens and improved adherence could
achieve virus suppression without the use of new classes of
antiretrovirals.
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